Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Abstract
Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface molecules. The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved...
Paper Details
Title
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Published Date
Mar 30, 2017
Journal
Volume
34
Issue
5
Pages
1015 - 1035
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History